Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467842 | 1.00 | MTNR1A (0.46) | MTNR1AMTNR1BSMN1; SMN2NPSR1MEN1 | |
| SCHEMBL2464892 | 0.84 | MTNR1A (0.51) | MTNR1AMTNR1BSMN1; SMN2NPSR1KMT2A | |
| SCHEMBL8522957 | 0.83 | MTNR1A (0.56) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL24011024 | 0.82 | CNR1 (0.50) | MTNR1AMTNR1BSMN1; SMN2NPSR1MAPK1 | |
| SCHEMBL2736653 | 0.82 | MTNR1A (0.47) | MTNR1AMTNR1BSMN1; SMN2NPSR1MEN1 | |
| SCHEMBL2736650 | 0.82 | MTNR1A (0.47) | MTNR1AMTNR1BSMN1; SMN2NPSR1MEN1 | |
| SCHEMBL14348198 | 0.81 | EPHX2 (0.49) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL8310630 | 0.81 | EPHX2 (0.49) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL14348200 | 0.80 | MTNR1A (0.42) | MTNR1AMTNR1BGRM7 | |
| SCHEMBL27203790 | 0.80 | MTNR1A (0.42) | MTNR1AMTNR1BGRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | NOVARTIS PHARMA AG (CH) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | MME, ACE, REN | MTNR1A 1875/4885MTNR1B 1578/4885SMN1; SMN2 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.